[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,75,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100616702","phase-1-phase-1-study-of-the-safety-and-pharmacokinetics-of-yn001-with-rosuvastatin-in-healthy-chinese-subjects-100616702",false,"NCT07309042","Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects","A Randomized, Open-label Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of the Combination of YN001 and Oral Rosuvastatin Calcium Tablets in Healthy Chinese Individuals","Inclusion Criteria:\n\n1. Fully understand the purpose, characteristics, research methods and potential adverse reactions of this study, voluntarily participate in the study as a subject, and sign the Informed Consent Form (ICF) before any assessments are performed.\n2. Healthy Chinese male and female subjects aged 18 to 55 years (inclusive, based on the age at the time of signing the ICF).\n3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) ranging from 18 to 28 kg\u002Fm² (including the critical values).\n4. Judged by the investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) and viral serological test results (normal or abnormal without clinical significance) to be in good general health.\n5. Female subjects must be non-pregnant and non-lactating; female subjects of childbearing potential (including female partners of male subjects) must agree to use effective contraceptive methods such as abstinence, condoms, intrauterine devices in use, double barrier methods (e.g., condoms plus diaphragms) from the screening period until 6 months after receiving the last dose of the study drug.\n6. Willing and able to comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Participation in other clinical trials within 3 months prior to the first dose or within 5 half-lives (whichever is longer). Subjects who withdrew from the study before receiving the study drug (i.e., not administered the drug) are eligible for enrollment.\n2. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health supplements within 2 weeks prior to the first dose, or receipt of any type of vaccination.\n3. Consumption of diets that may affect the in vivo metabolism of drugs (including grapefruit or grapefruit products, pitaya, mango, etc.) within 7 days prior to screening, engagement in strenuous exercise, or consumption of other diets that the investigator deems may affect the absorption, distribution, metabolism, or excretion of drugs.\n4. History of severe food allergies (e.g., anaphylactic shock). Mild food allergies such as lactose intolerance and glucose intolerance are not excluded.\n5. Allergy to multiple drugs, history of allergy to rosuvastatin, or history of allergic reactions to any component of the study drugs.\n6. Known presence of clinically significant abnormal diseases or factors, including but not limited to clinically significant abnormalities in abdominal color Doppler ultrasound (liver, gallbladder, spleen, pancreas, bilateral kidneys, ureters, urinary bladder), chest posteroanterior radiography, etc.; or clinically significant diseases (including but not limited to diseases of the digestive system, circulatory system, respiratory system, endocrine system, urinary system, immune system, nervous system, and mental and psychological diseases) shown by other clinical findings within 6 months prior to screening.\n7. History of myopathy\u002Fmyalgia, or predisposition to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, previous combined use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors and fibrates, etc.).\n8. Presence of hypothyroidism or hyperthyroidism.\n9. History of acute or chronic bronchospastic diseases (including asthma, chronic obstructive pulmonary disease, whether treated or not) or heart failure, myocardial infarction, with a history of onset or recurrence within the past 3 years.\n10. Known history of inflammatory bowel disease, ulcers, gastrointestinal bleeding, or rectal bleeding within 6 months prior to the first dose.\n11. History of pancreatic injury or pancreatitis within 6 months prior to dosing.\n12. Presence of symptoms of urinary tract obstruction or dysuria.\n13. History of autonomic nervous system disorders (e.g., recurrent syncope, palpitations, etc.), with a history of onset or recurrence within the past 3 years.\n14. Suffering from a major unhealed disease within 2 weeks prior to the first dose; or expected to undergo major surgery during the study period.\n15. History of renal impairment, manifested by clinically significant abnormalities in creatinine, blood urea nitrogen (BUN) and\u002For urea levels, or clinically significant abnormalities in urine components (e.g., proteinuria).\n16. Presence of liver disease or liver injury, or abnormal liver function test results. Subjects who meet any of the following criteria must be excluded from the study:\n\n    1. Any one of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum bilirubin exceeds 1.5 times the upper limit of normal (ULN).\n    2. Any two or more of ALT, AST, or serum bilirubin exceed the upper limit of normal (ULN).\n17. History of clinically significant electrocardiogram (ECG) abnormalities; or presence of any of the following abnormalities during screening or baseline period:\n\n    1. QTcF (males) \\> 470 milliseconds (msec).\n    2. QTcF (females) \\> 480 milliseconds (msec). (Corrected by the Frederica formula, calculated as QTcF = QT\u002F(RR⁰·³³))\n18. Screening test shows hemoglobin level \\\u003C 120 grams per liter (g\u002FL) in males and \\\u003C 110 grams per liter (g\u002FL) in females.\n19. Blood donation or blood loss exceeding 400 milliliters (mL) within 3 months prior to screening.\n20. Smoking more than 10 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening.\n21. History of drug abuse within 12 months prior to screening; or use of any illegal drugs within 3 months prior to screening; or positive results in drug abuse tests (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, morphine, etc.) during screening.\n22. Weekly alcohol consumption exceeding 14 standard drinking units (1 standard drinking unit = 285 mL of beer, or 25 mL of spirits, or 150 mL of wine) within 3 months prior to screening; or consumption of alcohol-containing products within 48 hours prior to the first dose; or positive results in breath alcohol test during the baseline period.\n23. Positive results in tests for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody.\n24. The investigator deems the subject unsuitable for participation in the study due to any other diseases or conditions.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The primary objective of this study is to investigate the safety and tolerability of YN001 in combination with rosuvastatin, so as to provide evidence for the feasibility of YN001 combined with statins in subsequent clinical trials.",[28,29],"Atherosclerotic Cardiovascular Diseases","Cerebrovascular Diseases","NOT_YET_RECRUITING","2025-12-15",{"date":33,"type":34},"2025-12-30","ACTUAL",{"date":36,"type":22},"2025-12",{"date":38,"type":22},"2026-02",{"name":40,"class":41},"Beijing Inno Medicine Co., Ltd.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100599877","rehabilitation-intervention-for-copd-combined-with-cardiovascular-and-cerebrovascular-diseases-100599877","NCT07090200","Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases","RI-COPD & CCD","Inclusion Criteria:\n\n1. Committed to adhering to the study protocol and cooperating with the implementation of the entire research process.\n2. Aged 18 years or older, regardless of gender.\n3. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with severe mental illness.\n2. Individuals assessed by medical personnel as having a disease that requires immediate hospitalization or a severe, uncontrollable condition that is life-threatening in the short term.\n3. Women who are pregnant, breastfeeding, or using inappropriate contraception methods.\n4. Individuals who refuse to cooperate with follow-up questionnaires or specimen collection.\n5. Patients currently participating in other interventional clinical drug trials.",{"count":50,"type":22},50000,[52],"NA","Firstly, to screen out the high-risk population of COPD combined with cardiovascular and cerebrovascular diseases, COPD with cardiovascular and make a diagnosis. Then, to evaluate the therapeutic effect of Pulmonary rehabilitation exercise and usual care for three months. And finally, to build a trinity model of rehabilitation management of COPD patients. The objective of this project is to establish and promote the application of diagnostic and treatment norms.",[55,56,29],"Respiratory Diseases","Cardiovascular Diseases",[58,59,60,61,62],"prevention","treatment strategies","respiratory diseases","cardiovascular diseases","cerebrovascular diseases","RECRUITING","2025-07-18",{"date":66,"type":34},"2025-07-29",{"date":68,"type":22},"2025-09-01",{"date":70,"type":22},"2028-07-31",{"name":72,"class":73},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":74},"100278887","genetic-metabolic-and-growth-factor-repository-for-cerebrovascular-disorders-100278887","NCT02910180","Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders","Inclusion Criteria:\n\n* All patients diagnosed with cerebral vascular disease, regardless of gender, age, ethnicity\u002Frace, stage of disease or treatment, are eligible.\n* Expected availability of clinical follow up data\n* Participants must be willing to provide written, informed consent obtained in accordance with institutional and federal guidelines.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from the study.",{"count":82,"type":22},900,"6 Months","OBSERVATIONAL","This study encompasses the maintenance and utilization of a repository of samples from patients with cerebrovascular disease and stroke. The types of tissue taken are blood, cerebrospinal fluid (CSF), tissue, and microdialysis samples. Future analysis of these samples can potentially help investigators to better categorize groups of patients, understand the underlying etiology of these pathologies, identify markers that are associated with favorable or poor outcomes, and track changes that occur during the natural course of the disease or with treatment. This is a prospective observational study which will use samples from such patients to create this library which can be used to explore these questions in the future.",[29,87,88],"Ischemic Stroke","Repository",[90,29,91,92,93,94,95,96,97,98],"Tissue Repository","Stroke","Aneurysm","Arteriovenous malformation","Fistula","Intracranial Stenosis","Treatment","Registry","Outcomes","2023-02-06",{"date":101,"type":34},"2023-02-08",{"date":103,"type":4},"2016-09",{"date":105,"type":22},"2030-12",{"name":107,"class":73},"Cedars-Sinai Medical Center",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":74},"100491743","cardiovascular-longitudinal-alspac-research-investigations-following-hypertensive-pregnancy-in-young-adulthood-100491743","NCT05683093","Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood","Cardiovascular Longitudinal the Avon Longitudinal Study of Parents and Children (ALSPAC) Research Investigations Following Hypertensive Pregnancy in Young Adulthood","CLARITY","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, aged 30 to 40 years at time of enrolment\n* Participant previously took part in the ALSPAC study\n* Able (in the investigator's opinion) and willing to comply with all study requirements\n* Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* Pregnant or lactating when they are due to attend for study visit 1\n* Less than six months postpartum\n* Planning to donate blood within two weeks prior to study visit 1\n* Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n* Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n\nFor exclusion of MRI component only:\n\n* Unsuitable for MRI based on participant screening; the participant may still be included in other parts of the study","30 Years","40 Years",{"count":119,"type":22},200,"The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.",[122,123,124,56,29,125],"Young Adult","Hypertension in Pregnancy","Hypertension","Vascular Diseases",[122,127,123,128,129],"Birth History","Cardiovascular Risk","Exercise Capacity","2023-01-05",{"date":132,"type":34},"2023-01-12",{"date":134,"type":34},"2022-11-17",{"date":136,"type":22},"2027-01-31",{"name":138,"class":73},"University of Oxford"]